303 related articles for article (PubMed ID: 16609012)
61. Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells.
Qiao Y; Cao J; Xie L; Shi X
Arch Pharm Res; 2009 Sep; 32(9):1309-15. PubMed ID: 19784588
[TBL] [Abstract][Full Text] [Related]
62. HPV16E7 mediates HADC chromatin repression and downregulation of MHC class I genes in HPV16 tumorigenic cells through interaction with an MHC class I promoter.
Li H; Ou X; Xiong J; Wang T
Biochem Biophys Res Commun; 2006 Nov; 349(4):1315-21. PubMed ID: 16979588
[TBL] [Abstract][Full Text] [Related]
63. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
[TBL] [Abstract][Full Text] [Related]
64. E6/E7 oncoproteins of high risk HPV-16 upregulate MT1-MMP, MMP-2 and MMP-9 and promote the migration of cervical cancer cells.
Zhu D; Ye M; Zhang W
Int J Clin Exp Pathol; 2015; 8(5):4981-9. PubMed ID: 26191191
[TBL] [Abstract][Full Text] [Related]
65. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients.
de Boer MA; Jordanova ES; Kenter GG; Peters AA; Corver WE; Trimbos JB; Fleuren GJ
Clin Cancer Res; 2007 Jan; 13(1):132-8. PubMed ID: 17200347
[TBL] [Abstract][Full Text] [Related]
66. [Inhibition of HPV16 E6 oncogene in cervical cancer by RNA interference].
Niu XY; Peng ZL; Duan WQ; Wang H; Chen YY; Fan YJ; Cheng YF; Qian XL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):14-8. PubMed ID: 16468632
[TBL] [Abstract][Full Text] [Related]
67. SOCS1 [corrected] inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein.
Kamio M; Yoshida T; Ogata H; Douchi T; Nagata Y; Inoue M; Hasegawa M; Yonemitsu Y; Yoshimura A
Oncogene; 2004 Apr; 23(17):3107-15. PubMed ID: 15021916
[TBL] [Abstract][Full Text] [Related]
68. [Construction and expression characteristics in vitro of human papillomavirus type 16 E7 suicidal DNA vaccine].
Wang HR; Wang BN; Li WY; Zuo FQ; Li H; Jiang ZH; Shi QF; Li MY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 39(2):165-8. PubMed ID: 18630674
[TBL] [Abstract][Full Text] [Related]
69. Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines.
Steele C; Cowsert LM; Shillitoe EJ
Cancer Res; 1993 May; 53(10 Suppl):2330-7. PubMed ID: 7683572
[TBL] [Abstract][Full Text] [Related]
70. Effect of combined antisense oligodeoxynucleotides directed against the human papillomavirus type 16 on cervical carcinoma cells.
Márquez-Gutiérrez MA; Benítez-Hess ML; DiPaolo JA; Alvarez-Salas LM
Arch Med Res; 2007 Oct; 38(7):730-8. PubMed ID: 17845891
[TBL] [Abstract][Full Text] [Related]
71. Recombinant adeno-associated virus mediated RNA interference inhibits metastasis of nasopharyngeal cancer cells in vivo and in vitro by suppression of Epstein-Barr virus encoded LMP-1.
Li X; Liu X; Li CY; Ding Y; Chau D; Li G; Kung HF; Lin MC; Peng Y
Int J Oncol; 2006 Sep; 29(3):595-603. PubMed ID: 16865275
[TBL] [Abstract][Full Text] [Related]
72. Delivering antisense telomerase RNA by a hybrid adenovirus/ adeno-associated virus significantly suppresses the malignant phenotype and enhances cell apoptosis of human breast cancer cells.
Zhang X; Chen Z; Chen Y; Tong T
Oncogene; 2003 Apr; 22(16):2405-16. PubMed ID: 12717417
[TBL] [Abstract][Full Text] [Related]
73. Up-regulation of vascular endothelial growth factor-C by nicotine in cervical cancer cell lines.
Lane D; Gray EA; Mathur RS; Mathur SP
Am J Reprod Immunol; 2005 Mar; 53(3):153-8. PubMed ID: 15727570
[TBL] [Abstract][Full Text] [Related]
74. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells.
Rincon-Orozco B; Halec G; Rosenberger S; Muschik D; Nindl I; Bachmann A; Ritter TM; Dondog B; Ly R; Bosch FX; Zawatzky R; Rösl F
Cancer Res; 2009 Nov; 69(22):8718-25. PubMed ID: 19887612
[TBL] [Abstract][Full Text] [Related]
75. Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells.
Lea JS; Sunaga N; Sato M; Kalahasti G; Miller DS; Minna JD; Muller CY
Reprod Sci; 2007 Jan; 14(1):20-8. PubMed ID: 17636212
[TBL] [Abstract][Full Text] [Related]
76. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses.
Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X
Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969
[TBL] [Abstract][Full Text] [Related]
77. The relationship between c-FLIP expression and human papillomavirus E2 gene disruption in cervical carcinogenesis.
Wang W; Wang S; Song X; Sima N; Xu X; Luo A; Chen G; Deng D; Xu Q; Meng L; Lu Y; Ma D
Gynecol Oncol; 2007 Jun; 105(3):571-7. PubMed ID: 17433827
[TBL] [Abstract][Full Text] [Related]
78. Human papillomavirus 16E6 suppresses major histocompatibility complex class I by upregulating lymphotoxin expression in human cervical cancer cells.
Kim DH; Kim EM; Lee EH; Ji KY; Yi J; Park M; Kim KD; Cho YY; Kang HS
Biochem Biophys Res Commun; 2011 Jun; 409(4):792-8. PubMed ID: 21621523
[TBL] [Abstract][Full Text] [Related]
79. Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase.
Smahel M; Pokorná D; Macková J; Vlasák J
J Gene Med; 2004 Oct; 6(10):1092-101. PubMed ID: 15386741
[TBL] [Abstract][Full Text] [Related]
80. [Expression, purification, and serum antibody detection of HPV16 E6 in cervical cancer patients].
Gao YE; Guo JZ; Zhang J; Song TB; Yan XJ
Ai Zheng; 2006 Nov; 25(11):1374-9. PubMed ID: 17094904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
